{"id":133721,"date":"2022-09-02T09:28:08","date_gmt":"2022-09-02T13:28:08","guid":{"rendered":"https:\/\/44.250.171.167\/?p=133721"},"modified":"2022-10-06T05:01:50","modified_gmt":"2022-10-06T09:01:50","slug":"gufic-biosciences-limited-q1-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/gufic-biosciences-limited-q1-fy23-earnings-conference-call-insights\/","title":{"rendered":"Gufic Biosciences Limited Q1 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><span class=\"embed-youtube\" style=\"text-align:center; display: block;\"><iframe loading=\"lazy\" class=\"youtube-player\" width=\"640\" height=\"360\" src=\"https:\/\/www.youtube.com\/embed\/l4VNZKKcWGw?version=3&#038;rel=1&#038;showsearch=0&#038;showinfo=1&#038;iv_load_policy=1&#038;fs=1&#038;hl=en-US&#038;autohide=2&#038;wmode=transparent\" allowfullscreen=\"true\" style=\"border:0;\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-presentation allow-popups-to-escape-sandbox\"><\/iframe><\/span><\/p>\n<p><strong>Key highlights from Gufic Biosciences Limited (<a href=\"https:\/\/44.250.171.167\/symbol\/GUFICBIO\/\">GUFICBIO<\/a>) Q1 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>Girish Gulati asked about pancreatic cancer update and is the company trying to target any hospitals. Pranav Chokshi CEO answered that GUFICBIO is currently following certain animal models as per the regulatory pathway. The company is looking at, at least some time off till it start the human trials in India.<\/li>\n<\/ul>\n<ul>\n<li>Rajat Setiya with ithought PMS asked about the INR3,000 crore market of dual chamber and the conventional vials. \u00a0Pranav Chokshi CEO replied that the entire INR3,000 crores market is conventional vial only. GUFICBIO is the first one to come to dual chamber and then will be taking the market share from this.<\/li>\n<\/ul>\n<ul>\n<li>Rajat Setiya with ithought PMS asked about the revenue potential from dual chamber in next two years and if there will more variants of this product. Pranav Chokshi CEO answered that anything that can be done intravenously can be done in this product from 50 mg to 5 gms. Overall, the target of minimum 15-20% YoY revenue jump will be coming and this product will be playing a big role.<\/li>\n<\/ul>\n<ul>\n<li>Rajat Setiya with ithought PMS asked if the company is seeing any more people entering dual chamber bag in the immediate future. Pranav Chokshi CEO clarified that as of now GIFUCBIO is not seeing anyone entering. For the company it took 4 years to get it done. So for next 2 years, GIFICBIO is not seeing a competition.<\/li>\n<\/ul>\n<ul>\n<li>Pujan Shah of Congruence asked about dydrogesterone and why GUFICBIO is only targeting INR20 crore of INR700 crore market. Pranav Chokshi CEO said two years ago the market was only of 1-2 players. Now there are 3-4 players and it\u2019s a complex product to work on.<\/li>\n<\/ul>\n<ul>\n<li>Pujan Shah of Congruence asked about the percentage wise breakup of domestic business and total revenue. Pranav Chokshi CEO replied that the domestic business is always around 50%, 55% of the company\u2019s total revenue.<\/li>\n<\/ul>\n<ul>\n<li>Ankit Minocha from MRLR Capital enquired if the EBITDA margin of 20% sustainable for the coming year. Devkinandan Roonghta CFO answered that the company feels that looking to the current business scenario, it will be able to maintain the EBITDA margin for this year at least 20% and it can go up to 21% also, depending upon the product mix and prices in the international market of the API prices.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Gufic Biosciences Limited (GUFICBIO) Q1 FY23 Earnings Concall Q&amp;A Highlights: Girish Gulati asked about pancreatic cancer update and is the company trying to target any hospitals. Pranav Chokshi CEO answered that GUFICBIO is currently following certain animal models as per the regulatory pathway. The company is looking at, at least some time [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Gufic Biosciences Limited Q1 FY23 Earnings Conference Call Insights #GUFICBIO #Q1 #FY23 #Earnings","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[1115],"class_list":["post-133721","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":142501,"url":"https:\/\/alphastreet.com\/india\/gufic-biosciences-limited-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133721,"position":0},"title":"Gufic Biosciences Limited Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"February 22, 2023","format":false,"excerpt":"Key highlights from Gufic Biosciences Limited (GUFICBIO) Q3 FY23 Earnings Concall Q&A Highlights: [00:11:06] Gunit Singh from CCIPL enquired about the driver of operating margin jump for YTD 9 months and if it will sustain in future. D.B.Roonghta CFO replied that the increase in turnover did not increase the fixed\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":128245,"url":"https:\/\/alphastreet.com\/india\/gufic-biosciences-limited-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":133721,"position":1},"title":"Gufic Biosciences Limited Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"March 14, 2022","format":false,"excerpt":"https:\/\/youtu.be\/f3tlyxhD91U Key highlights from Gufic Biosciences Limited (GUFICBIO) Q3 FY22 Earnings Concall Management Update: In CDMO, GUFICBIO said it\u2019s looking at a 9.4 million vials capacity per month which should make the company the largest manufacturer in the world. Q&A Highlights: Umang Shah from Sarath Capital AIF asked that the\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":156403,"url":"https:\/\/alphastreet.com\/india\/gufic-biosciences-limited-q2-fy24-earnings-conference-call-insights\/","url_meta":{"origin":133721,"position":2},"title":"Gufic Biosciences Limited Q2 FY24 Earnings Conference Call Insights","author":"Praveen","date":"November 17, 2023","format":false,"excerpt":"Key highlights from Gufic Biosciences Limited (GUFICBIO) Q2 FY24 Earnings Concall New Product Launches and Approvals Launched new products like Dalbavancin and SeraSeal across divisions. The company received regulatory approvals for products in markets like Sri Lanka, Chile, Malaysia, Australia and Brazil. Expecting approvals for Immunocin-Alpha and dual-chamber bags with\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":154805,"url":"https:\/\/alphastreet.com\/india\/gufic-biosciences-advancements-strategic-developments-in-pharmaceuticals\/","url_meta":{"origin":133721,"position":3},"title":"Gufic BioSciences: Advancements &#038; Strategic Developments in Pharmaceuticals","author":"Hardik Bhandare","date":"October 11, 2023","format":false,"excerpt":"\u201cWe are also happy to announce that Gufic has secured DCGI approval for the manufacturing and marketing of Dalbavancin and we are the first Company to receive such approval in India. Trial for sepsis involving Immunocin Alpha have completed successfully and we anticipate the DGCI approval by Q3 of this\u2026","rel":"","context":"In &quot;Research Summary&quot;","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/b4654e61-a1d5-4b7f-8d9b-2f1140b01114-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/b4654e61-a1d5-4b7f-8d9b-2f1140b01114-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/b4654e61-a1d5-4b7f-8d9b-2f1140b01114-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/b4654e61-a1d5-4b7f-8d9b-2f1140b01114-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/b4654e61-a1d5-4b7f-8d9b-2f1140b01114-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/b4654e61-a1d5-4b7f-8d9b-2f1140b01114-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":137669,"url":"https:\/\/alphastreet.com\/india\/gufic-biosciences-limited-guficbio-q1-fy23-earnings-concall\/","url_meta":{"origin":133721,"position":4},"title":"Gufic Biosciences Limited (GUFICBIO) Q1 FY23 Earnings Concall","author":"IRS_INDIA","date":"November 13, 2022","format":false,"excerpt":"Gufic Biosciences Limited (NSE:GUFICBIO) Q2 FY23 Earnings Concall dated Nov.13, 2022 Corporate Participants: Ami Naresh Shah\u00a0--\u00a0Company Secretary and Compliance Officer Avik Das\u00a0--\u00a0Investor Relations Devakinandan B. Roonghta\u00a0--\u00a0Chief Financial Officer Pranav Jayesh Choksi\u00a0--\u00a0Chief Executive Officer and a Whole Time Director Analysts: Keshav Kumar\u00a0--\u00a0RakSan Investors -- Analyst Rajat Setiya\u00a0--\u00a0ithoughtpms -- Analyst Rohan Ravindra\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/pngtree-cartoon-mobile-phone-online-delivery-express-cart-illustration-png-image_2160013.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/pngtree-cartoon-mobile-phone-online-delivery-express-cart-illustration-png-image_2160013.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/pngtree-cartoon-mobile-phone-online-delivery-express-cart-illustration-png-image_2160013.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":136941,"url":"https:\/\/alphastreet.com\/india\/jb-chemicals-pharmaceuticals-limited-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133721,"position":5},"title":"JB Chemicals &#038; Pharmaceuticals Limited Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"November 17, 2022","format":false,"excerpt":"Key highlights from JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) Q2 FY23 Earnings Concall Management Update: [00:06:28] JBCHEPHARM said that in domestic markets it seeks to make its key brands stronger with a focus on building brand franchise in terms of market share and higher prescriptions. The company expects its domestic\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/133721","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=133721"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/133721\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=133721"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=133721"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=133721"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}